Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

7P - Peripheral blood-based biomarkers of prognosis and treatment response in patients with non-small cell lung cancer treated with PD-1 inhibitors

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Ioannis Tourkantonis

Citation

Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389

Authors

I. Tourkantonis1, D. Grapsa2, A. Charpidou2, I. Gkiozos2, H. Gogas2

Author affiliations

  • 1 Oncology Unit, Medical School, National and Kapodistrian University of Athens, Athens/GR
  • 2 Medical School, National and Kapodistrian University of Athens, Athens/GR
More

Abstract 7P

Background

To date, there remains an urgent need for more accurate biomarkers to predict clinical outcomes in patients with advanced-stage non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors. The primary aim of our study was to evaluate the prognostic and predictive value of peripheral blood-based biomarkers, both at baseline (pre-treatment) and post-treatment, in this challenging clinical setting.

Methods

A retrospective study of the clinicopathological features and treatment data of 117 patients with advanced-stage NSCLC, treated with nivolumab or pembrolizumab at the Oncology Unit of Sotiria Athens General Hospital, was performed. Baseline and post-treatment absolute counts of neutrophils (ANC), lymphocytes (ALC), monocytes (AMC), eosinophils (AEC) and platelets (PLT), LDH as well as the ratio of neutrophils to lymphocytes (NLR), platelets to lymphocytes (PLR) and myeloid to lymphoid cells (M:L) were correlated with treatment response, durable clinical benefit (defined as absence of disease progression at 6 months) and progression-free survival (PFS).

Results

58,1% of patients had no immune-related adverse events (IrAEs), while rash and hyperthyroidism were observed in 17.9% and 12.8% of patients, respectively. Durable clinical benefit (DCB) rates were significantly lower in patients with increased pretreatment ANC, AMC, PLT, NLR, PLR, M:L and PLT ≥ 400 K/μl as well as post-treatment ANC ≥ 7500/μl, AMC ≥ 650/μl, NLR ≥ 5 and PLR > 160. Increased pretreatment PLR and PLT ≥ 400K/μ as well as increased post-treatment ANC, AMC, PLT, NLR, PLR, M:L, LDH, ANC > 7500/μl, AMC > 650/μl, PLT > 400K/μl, NLR > 5 and PLR > 160 were all correlated with reduced PFS. In multivariate analysis, increased pretreatment PLR [HR (95% CI): 0,79 (0,63 − 0,99); p=0,040] was independently correlated with worse PFS.

Conclusions

Pre-treatment PLR may independently predict prognosis in advanced NSCLC patients treated with PD-1 inhibitors. With the exception of ALC and AEC, pretreatment and/or post-treatment levels of all remaining blood cell counts and indices evaluated were shown to correlate either with DCB and/or PFS, albeit only in univariate analysis.

Legal entity responsible for the study

Konstantinos Syrigos.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.